Fig. 5: ECHS1 contributes to aggressive phenotypes and drug resistance of CRC cells, both in vitro and in vivo. | Cell Death & Disease

Fig. 5: ECHS1 contributes to aggressive phenotypes and drug resistance of CRC cells, both in vitro and in vivo.

From: ECHS1, an interacting protein of LASP1, induces sphingolipid-metabolism imbalance to promote colorectal cancer progression by regulating ceramide glycosylation

Fig. 5

A Representative figures of the clone-formation assay for the indicated cells. Bars on the right represent the number of formed clones. B CCK-8 assay for ECHS1 loss- and gain-of-function analysis of SW480 cells and HCT116 cells on CRC cell proliferation. C CCK-8 assay for LV-Ctrl-, LV-LASP1-, and LV-LASP1 plus siRNA-ECHS1-transfected RKO cells. D, E LV-Ctrl and LV-ECHS1 HCT116 cells (D) and sgNC and sgECHS1 SW480 cells (E) were injected subcutaneously into the backs of nude mice to access tumor growth. The representative figures of the tumors are shown. The right bar represents the weight of the tumors. The double asterisk (**) indicates P < 0.01. F CCK-8 assay analysis of cell viability with gradient application of 5-Fluorouracil and Oxaliplatin. G LV-Ctrl and LV-ECHS1 HCT116 cells were injected subcutaneously into the backs of nude mice with or without Oxaliplatin (1.5 mg/kg) and Eliglustat (60 mg/kg) to evaluate tumor growth. A representative figure of the tumors is shown. The right bar represents the weight of the tumors. H Subcellular localization of Ki-67, p-mTOR, Beclin1, and BCL2 in the indicated cells was assessed through immunohistochemical staining.

Back to article page